TrialTexas Heart Institute journal2010

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Jay H Traverse et al.PubMed ↗Full text ↗

No numbers read from the abstract.